CDK1

Cyclin-dependent kinase 1

270,781 patent compounds predicted against CDK1, 172,140 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Kenpaullone (SCHEMBL79889)	1.00	19/20
Aloisine (SCHEMBL79714)	1.00	18/20
Aloisine A (SCHEMBL80147)	1.00	18/20
Methylguanine (SCHEMBL34851)	0.51	17/20
Seliciclib (SCHEMBL94728)	1.00	14/20
Alvocidib (SCHEMBL3651)	1.00	11/20
Alvocidib (SCHEMBL3652)	1.00	11/20
2,6-Diaminopurine (SCHEMBL24053)	0.54	10/20
SCHEMBL19840	0.51	9/20
SCHEMBL25860	0.44	9/20
SCHEMBL12292	0.59	8/20
SCHEMBL91115	0.55	8/20
SCHEMBL19938	0.54	8/20
Purvalanol B (SCHEMBL27951)	1.00	7/20
6-O-Benzylguanine (SCHEMBL61740)	1.00	7/20
SCHEMBL23608	0.57	7/20
SCHEMBL12466	0.57	7/20
2-Aminopurine (SCHEMBL5634)	0.42	7/20
SCHEMBL84078	0.56	6/20
SCHEMBL84414	0.54	6/20

Germline variants in CDK1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CDK1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CDK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)	PHASE3	COMPLETED
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)	PHASE3	COMPLETED
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression	PHASE2	COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer	PHASE2	COMPLETED
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy	PHASE2	COMPLETED
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer	PHASE2	RECRUITING
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors	PHASE1/PHASE2	COMPLETED
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)	PHASE1/PHASE2	RECRUITING
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma	PHASE1/PHASE2	RECRUITING
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors	PHASE1/PHASE2	COMPLETED
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC	PHASE2	ACTIVE_NOT_RECRUITING
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer	PHASE2	WITHDRAWN
CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO	PHASE2	COMPLETED
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6	PHASE2	RECRUITING
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors	PHASE1/PHASE2	RECRUITING
Abemaciclib With or Without Atezolizumab for mCRPC	PHASE2	COMPLETED
Efficacy and Safety of Avatrombopag in Cancer Patients With Thrombocytopenia	PHASE2	UNKNOWN
Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.	PHASE2	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms	PHASE1	COMPLETED
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers	PHASE1	COMPLETED
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	PHASE1	COMPLETED
Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma	PHASE1	WITHDRAWN
Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study	nan	ACTIVE_NOT_RECRUITING
Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy	nan	COMPLETED
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period	nan	UNKNOWN
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CDK1 binder may also engage these)

Protein	Name	Similarity
Q5RCH1	—	1.000	Q5RCH1 →
Q9W739	—	1.000	Q9W739 →
P48734	—	1.000	P48734 →
Q9DGD3	—	1.000	Q9DGD3 →
P13863	—	1.000	P13863 →
Q4Z6R1	—	1.000	Q4Z6R1 →
P51166	—	1.000	P51166 →
Q9XZD6	—	1.000	Q9XZD6 →
P35567	—	0.999	P35567 →
Q9DGA5	—	0.999	Q9DGA5 →
P51958	—	0.999	P51958 →
O96821	—	0.999	O96821 →
Q9DGA2	—	0.998	Q9DGA2 →
P23572	—	0.997	P23572 →
P34117	—	0.997	P34117 →
P04551	—	0.997	P04551 →
P11440	—	0.997	P11440 →
Q03114	—	0.997	Q03114 →
P39951	—	0.996	P39951 →
P61075	—	0.996	P61075 →
Q6C7U8	—	0.995	Q6C7U8 →
Q2PQN9	—	0.995	Q2PQN9 →
P24100	—	0.995	P24100 →
Q4Y4B1	—	0.994	Q4Y4B1 →
Q27032	—	0.994	Q27032 →
CDK2	Cyclin-dependent kinase 2	0.994	landscape →
Q9DG98	—	0.994	Q9DG98 →
Q04770	—	0.994	Q04770 →
P24033	—	0.993	P24033 →
P48963	—	0.993	P48963 →